Lifeline Sci Share Discussion Threads

[sailing john] 20/6/2016 12:08

Yes AGM this Thursday - hopefully a TS on that day - edit as I assume nobody going!
SJ

[5oletrader] 20/6/2016 11:54

Days away...

"The Board can confirm that, while the final outcome of the strategic review has not yet been reached, it is in discussions with a number of interested parties which may or may not lead to an offer for the Company. While no assurances can be made as to the outcome of these discussions, progress has been made towards a strategy which the Board believes will enhance value for shareholders. The Board expects to be in a position to provide a further update on the progress of the strategic review process by the end of June 2016."

[battlebus2] 05/5/2016 11:34

Profit taking....

[interceptor2] 03/5/2016 17:48

Noticed that one battlebus, there was another larger trade of 5658 over the bid at 309p. Must be a very difficult stock to build a worthwhile holding for the bigger boys, unless they could find a willing seller.

[battlebus2] 03/5/2016 17:15

Someone's keen paying 316 for just over 6k shares.

[2vdm] 29/4/2016 09:12

Like you Somerset lad, I've been sitting on these since 2011 at £2.20, so hardly what could be described as a good investment to date, but lets hope it grows exponentially from here on

[eezymunny] 28/4/2016 16:28

Indeed Lad. It's not just the net cash either - there's c. $18m in net current assets. While we're getting all optimistic ;)

[somerset lad] 28/4/2016 15:52

The trailing earnings of course come only from the kidney product. The business has some very attractive characteristics: limited direct competitors (for the equipment), long lead times for rival products to win approval and establish themselves, and excellent growth prospects generally and especially in China. It wouldn't be at all surprising to see a business like this on a trailing PE of 20-25 or more.

And you need to add the liver product. Although not finally approved, the prospects for this getting to market look very strong given the research to date and the potential earnings over the product's lifecycle seem significant. Medical devices development companies with products of this type near to market commonly command quite large market caps.

So if you add the two together (and stir in the net cash and the tax losses), I get a higher valuation than cfro, and it's one of my largest holdings as a result (although I bought much too early, from March 2011...).

[eezymunny] 28/4/2016 14:16

I'm rather hopeful of something in that region cfro but I guess all will depend on a buyers judgement of competitive position. If you Google about there doesn't seem to be anything else there that competes well. That of course can change.

To me it just doesn't seem expensive enough here to warrant selling any. Events may prove me wrong!

[cfro] 28/4/2016 13:52

If there happens to be a takeover here, i wonder as to what price the bid might be pitched at?

With 20p eps in the bag, for starters one could say a price of 400p using a historic multiple of 20 which is very fair imo.

Put another way one could project the growth in earnings out a year or two and say 25p eps and a multiple of 16 which would give the same result.

[battlebus2] 28/4/2016 09:23

Continuing the rise...:))

[zipstuck] 27/4/2016 12:48

The Board can confirm that, while the final outcome of the strategic review has not yet been reached, it is in discussions with a number of interested parties which may or may not lead to an offer for the Company. While no assurances can be made as to the outcome of these discussions, progress has been made towards a strategy which the Board believes will enhance value for shareholders. The Board expects to be in a position to provide a further update on the progress of the strategic review process by the end of June 2016.

[zipstuck] 27/4/2016 12:46

I'll wait for the takeover - it's in play at a PE of < 15

[somerset lad] 27/4/2016 09:22

They have always expensed all their R&D and the spend has fallen as they've nearly finished developing liver and have no plans to develop for a third organ. The payback for expensing R&D is higher profits.

[eezymunny] 27/4/2016 09:20

True spooky but the previous higher R&D spend was to get the liver transporter ready. One would hope that the lower level of R&D is now the norm (unless they start on something new of course!)

[spooky] 27/4/2016 08:58

EPS was up because of a crunch in R&D spending.

[eezymunny] 27/4/2016 08:46

Adj eps was c. 19.5p so P/e c. 13 at 250p. Adjusted for net cash of c. £4.8m for a P/E of under 12 (perhaps c. 5% higher allowing for dilutive options etc). That could be viewed as pretty cheap for a patent protected, market leading product company with a global market, new products coming etc.

I guess new business is pretty lumpy and the risk, as ever, is somebody coming along with a better solution (like an organ printing machine - prob not too far fetched!)

I shall hold on til end June and see what the outcome is. It might just sell for a big premium. Or not :)

[sailing john] 27/4/2016 08:27

Yes cracking results as expected - I like the word inflection point!

Pleased with the strategic review commentary

And of course PBT in 1H was only $0.1m so the entire profit was delivered in 2H. Whilst 2H is typically stronger than 1H I find it hard to believe that sequentially 1H 2016 won't also be very strong compared to 2015.

GL - SJ

[interceptor2] 27/4/2016 08:14

Very pleased with the results, benefitting from higher tax credits this year makes balance sheet even more attractive to any potential interested party.

Looks like an offer will come at some point imo.

[battlebus2] 27/4/2016 08:04

Yes excellent, can't see them in the present form for much longer.

[cfro] 27/4/2016 08:01

Very strong results.

63cents basic eps a significant increase in profitability.

Potential offer.

[horgan] 27/4/2016 07:51

The Board can confirm that, while the final outcome of the strategic review has not yet been reached, it is in discussions with a number of interested parties which may or may not lead to an offer for the Company. While no assurances can be made as to the outcome of these discussions, progress has been made towards a strategy which the Board believes will enhance value for shareholders. The Board expects to be in a position to provide a further update on the progress of the strategic review process by the end of June 2016.

[battlebus2] 22/4/2016 16:03

Yes i'd hope early next week cfro....

[cfro] 22/4/2016 15:57

Had another top-up here.

Some good buying today combined with tight stock is having an upwards effect on the price.

Results due 'towards the end of April' so could be any day now.

[battlebus2] 15/4/2016 08:01

Should bring these to the attention of a few more :))